OR WAIT null SECS
January 03, 2019
AbbVie and immunotherapy company Tizona Therapeutics will join forces to develop and commercialize CD39-targeted therapeutics to treat cancer.
December 18, 2018
Agilent and other partners are funding development of Tapestri, a single-cell sequencing platform designed to help predict cancer relapse in individual patients and show the efficacy of gene-editing experiments.
December 14, 2018
Avacta Group and LC Chem Life Sciences have entered into a multi-target collaboration and development agreement.
December 05, 2018
GSK and TESARO have entered into a definitive agreement concerning GSK's acquisition of TESARO for an aggregate cash consideration worth approximately $5.1 billion.
December 02, 2018
Antibody-based drugs offer new mechanisms of action and greater specificity.
November 29, 2018
The partnership, co-funded by Enterprise Ireland, will develop technologies for monitoring the quality of biopharma processes.
November 16, 2018
Moving forward with gene therapy development requires a “quantum leap” in manufacturing capabilities.
November 15, 2018
The testing of raw materials is essential as raw material quality determines the outcome of biologic product quality.
November 09, 2018
The new program will provide cell and gene therapy companies a more efficient way to ensure quality compliance across collection center networks and to minimize quality system audit burden on these centers.
November 02, 2018
The company received FDA approval for Hyrimoz (adalimumab-adaz), its biosimilar referencing AbbVie’s blockbuster Humira (adalimumab).